Pharma growth trumps uncertainty in early election reactions

9 November 2016
2019_biotech_test_vial_discovery_big

Rather than uncertainty about what the Presidency of Donald Trump might mean for drug prices, many pharma and biotech stocks jumped considerably after the Republican nominee gained a shock election victory over Democrat Hillary Clinton.

Many US drugmakers leapt overnight, including pharma giants Merck & Co (NYSE: MRK), which was nearly 5% up on the previous evening after an hour’s trading on Tuesday, and Pfizer (NYSE: PFE), which was trading almost 8% higher at the same time. This was after they had settled down having initially opening at even higher rates.

US biotechs were also up, with Amgen (Nasdaq: AMGN) and Gilead more than 4% higher, and Regeneron rising 8%.
Internationally it was a similar story, with Swiss pharma giants Novartis (NOVN: VX) and Roche (ROG: SIX) climbing 5% and France’s Sanofi (Euronext: SAN) up 4%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology